Editorial Videos

In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses what to expect from the obesity space in the next five years.

In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses why their drug isn't experiencing the same supply issues as the bigger names in the space.

In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses factors that are contributing to ongoing supply issues and if prices for these therapies are coming down anytime soon.

In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses how a personalized approach in obesity treatment can benefit access.

In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses how access to these weight loss drugs can help the obesity epidemic.

In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, talks about the ethical and regulatory problems weight loss companies like WW, Noom, and Ro present.

In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, talks about how different kinds of therapies perform and fit in in the current business landscape.

In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses their drug Contrave and the data they have to show after a 10 years in the weight loss/obesity space.

In this Pharmaceutical Executive video interview, Optum Rx clinical pharmacist, Arash Sadeghi, discusses upcoming advancements in the drug pipeline and trends shaping the future of drug development.

In this Pharmaceutical Executive video interview, Optum Rx clinical pharmacist, Arash Sadeghi, discusses how healthcare providers and patients navigate the potential benefits and uncertainties associated with a medication approved through the accelerated approval pathway.

In an interview with Pharm Exec Associate Editor Don Tracy, Fady Boctor, President, Chief Commercial Officer, Petros Pharmaceuticals talks about the recent availability of Opill as an over-the-counter (OTC) contraceptive.

In this Pharmaceutical Executive video interview, Marie Teil, Global Head of UCB’s Women of Childbearing Age Program, discusses the specific challenges women with chronic illnesses face when it comes to accessing and participating in clinical research.

In this Pharmaceutical Executive video interview, Optum Rx clinical pharmacist, Arash Sadeghi, explore mixed trial results impact the confidence in their potential real-world effectiveness and potential market adoption.

In this Pharmaceutical Executive video interview, Marie Teil, Global Head of UCB’s Women of Childbearing Age Program, talks about the program's creation and their most successful strategies for encouraging the inclusion of women of childbearing age in clinical trials.

In this Pharmaceutical Executive video interview, Optum Rx clinical pharmacist, Arash Sadeghi, discusses the three drugs featured in their Drug Pipeline Insights Report for 2024 and which unmet needs they address.

In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, talks about what's coming marketing with the use of AI.

In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, talks about how he has successfully combined cutting-edge technologies with traditional marketing approaches in his past ventures.

In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, explains utilizing generative AI for rapid content creation and how AI-driven automation of that content distribution has increased visibility.

In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, discusses the impact AI will have on thelong-term well-being of founders and CEOs.

In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses why no novel active substances have yet been brought to market through AI technology despite increasing investments in the space for drug discovery as shown in IQVIA's Global Trends in R&D 2024 report.

In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, discusses how AI could have helped address past challenges.

In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses findings from IQVIA's Global Trends in R&D 2024 report including the potential benefits and limitations of novel trial designs and decentralized methodologies.

In this Pharmaceutical Executive interview, Jill Jaroch, Senior Director, Women’s Health & Urology Marketing at Astellas, discusses the decision to continue VEOZAH's presence during the big game, the inspiration and message behind the commercial, and if Taylor Swift played a factor in their decision making

In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses findings from IQVIA's Global Trends in R&D 2024 report that shows why the US continued to lead in new drug launches in 2023.

In this Pharmaceutical Executive video interview, Chris Dowd, senior vice president of market development, ConnectiveRx, discusses the evolution of drug copay adjustment programs and the circumstances that fueled their controversy across industry, political, and healthcare community circles.

In this Pharmaceutical Executive video interview, Daniel Ayala, Chief Security and Trust Officer, Dotmatics discusses how the data integrity landscape will evolve over the next five years and what extent bench scientists in the lab focused on data integrity.

In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses the biggest challenges facing the broader adoption of novel cell and gene therapies from IQVIA's Global Trends in R&D 2024 report.

In this Pharmaceutical Executive interview, Daniel Ayala, Chief Security and Trust Officer, Dotmatics, dives into the greatest threats to the integrity of data in R&D and threats presented by hackers.